Considering ivermectin for treatment of schistosomiasis.
Schistosoma mansoni
Ivermectin
Parasites
Praziquantel
Schistosomiasis
Treatment
Journal
Parasitology research
ISSN: 1432-1955
Titre abrégé: Parasitol Res
Pays: Germany
ID NLM: 8703571
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
received:
21
09
2023
accepted:
29
02
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
9
4
2024
Statut:
epublish
Résumé
Because of recent reports of praziquantel resistance in schistosome infections, there have been suggestions to employ ivermectin as a possible alternative, especially as its chemical composition is different from that of praziquantel, so cross-resistance is not expected. In order to ascertain possible damage and elimination of worms, we used ivermectin by oral gavage in infected mice, at a high dose (30.1 mg/kg, bordering toxicity). We also tested the efficacy of the drug at various times postinfection (PI), to check on possible effect on young and mature stages of the parasites. Thus, we treated mice on days 21 and 22 or on days 41 and 42 and even on days 21, 22, 41, and 42 PI. None of the treatment regimens resulted in cure rates or signs of lessened pathology in the mice. We also compared the effect of ivermectin to that of artemisone, an artemisinin derivative which had served us in the past as an effective anti-schistosome drug, and there was a stark difference in the artemisone's efficacy compared to that of ivermectin; while ivermectin was not effective, artemisone eliminated most of the worms, prevented egg production and granulomatous inflammatory response. We assume that the reported lack of activity of ivermectin, in comparison with praziquantel and artemisinins, originates from the difference in their mode of action. In wake of our results, we suggest that ivermectin is not a suitable drug for treatment of schistosomiasis.
Identifiants
pubmed: 38592544
doi: 10.1007/s00436-024-08178-1
pii: 10.1007/s00436-024-08178-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Informations de copyright
© 2024. The Author(s).
Références
Acharya S, Da’daraSkelly AAPJ (2021) Schistosome immunomodulators. PLoS Pathog 202117(12):e1010064
doi: 10.1371/journal.ppat.1010064
Agere H, Kela SL, Istifanus WA (2014) Chemotherapeutic trials of praziquantel and ivermectin on victims of urinary schistosomiasis in Taraba North Senatorial District; Nigeria. Sci-Afric J Sci Issues Res Essays 2:156–159
Alwan SN, Taylor AB, Rhodes J et al (2023) Oxamniquine derivatives overcome praziquantel treatment limitations for schistosomiasis. PLoS Pathog 19(7):e1011018
pubmed: 37428793
pmcid: 10359000
doi: 10.1371/journal.ppat.1011018
Aruleba RT, Adekiya TA, Oyinloye BE et al (2019) PZQ Therapy: how close are we in the development of effective alternative anti-schistosomal drugs? Infect Disord Drug Targets 19:337–349
pubmed: 30599112
pmcid: 7046992
doi: 10.2174/1871526519666181231153139
Barda B, Coulibaly JT, Puchkov M et al (2016) (2016) Efficacy and safety of moxidectin, synriam, synriam-praziquantel versus praziquantel against Schistosoma haematobium and S mansoni infections: a randomized, exploratory phase 2 trial. PLoS Negl Trop Dis. 10(9):e0005008
pubmed: 27636542
pmcid: 5026339
doi: 10.1371/journal.pntd.0005008
Beutler M, Harnischfeger J, Weber MHW et al (2023) Identification and characterisation of the tegument-expressed aldehyde dehydrogenase SmALDH_312 of Schistosoma mansoni, a target of disulfiram. Eur J Med Chem 251:115179
pubmed: 36948075
doi: 10.1016/j.ejmech.2023.115179
Blakley BR, Rousseux CG (1991) Effect of ivermectin on the immune response in mice. Am J Vet Res 52:593–595
pubmed: 1828942
doi: 10.2460/ajvr.1991.52.04.593
Brattig NW, Cheke RA, Garms R (2021) Onchocerciasis (river blindness) - more than a century of research and control. Acta Trop 218:105677
pubmed: 32857984
doi: 10.1016/j.actatropica.2020.105677
Brindley PJ, Sher A (1990) Immunological involvement in the efficacy of praziquantel. Exp Parasitol 71:245–248
pubmed: 2115457
doi: 10.1016/0014-4894(90)90028-B
Caldwell N, Afshar R, Baragaña B et al (2023) Perspective on schistosomiasis drug discovery: highlights from a schistosomiasis drug discovery workshop at Wellcome Collection. London, ACS Infect Dis 9:1046–1055
pubmed: 37083395
doi: 10.1021/acsinfecdis.3c00081
Chen IS, Kubo Y (2018) Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin. J Physiol 596:1833–1845
pubmed: 29063617
doi: 10.1113/JP275236
Chulkov EG, Palygin O, Yahya NA (2023) Electrophysiological characterization of a schistosome transient receptor potential channel activated by praziquantel. Int J Parasitol 53:415–425
pubmed: 36610556
doi: 10.1016/j.ijpara.2022.11.005
Coutinho AB (1961) Bilharzian liver fibrosis. Am J Dig Dis 6:887–898
pubmed: 13696045
doi: 10.1007/BF02231085
Cunha VM, Noël F (1997) Praziquantel has no direct effect on (Na(+)+K+)-ATPases and (Ca2(+)-Mg2+)ATPases of Schistosoma mansoni. Life Sci. 60(20):289–94
doi: 10.1016/S0024-3205(97)00144-6
Da Silva VBR, Campos BRKL, de Oliveira JF et al (2017) Medicinal chemistry of anti-schistosomal drugs: praziquantel and oxamniquine. Bioorganic Med Chem 25:3259–3277
doi: 10.1016/j.bmc.2017.04.031
Dong L, Duan W, Chen J et al (2014) An artemisinin derivative of praziquantel as an orally active antischistosomal agent. PLoSONE 9(11):e112163
doi: 10.1371/journal.pone.0112163
Feng XP, Hayashi J, Beech RN et al (2002) Study of the nematode putative GABA type-A receptor subunits: evidence for modulation by ivermectin. J Neurochem 83:870–878
Huang SH, Wu CH, Chen SJ et al (2020) Immunomodulatory effects and potential clinical applications of dimethyl sulfoxide. Immunobiolog 225:151906
doi: 10.1016/j.imbio.2020.151906
Johnson-Arbor, (2022) Ivermectin: a mini-review. Clin Toxicol (phila) 60:571–575
pubmed: 35225114
doi: 10.1080/15563650.2022.2043338
Katz N, Araújo N, Coelho P et al (2017) Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of schistosomiasis. J Antibiot 70:680–684
doi: 10.1038/ja.2017.31
Keiser J, Utzinger J (2012) Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18:3531–3538
pubmed: 22607145
Kositz C, Bradley J, Hutchins H et al (2022) Broadening the range of use cases for ivermectin – a review of the evidence. Trans R Soc Trop Med Hyg 116:201–212
pubmed: 34323283
doi: 10.1093/trstmh/trab114
Laing R, Gillan V, Devaney E (2017) Ivermectin – old drug, new tricks? Trends Parasitol 33:463–472
pubmed: 28285851
pmcid: 5446326
doi: 10.1016/j.pt.2017.02.004
Le Clec’h W, Chevalier FD, Mattos ACA (2021) Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel. Sci Transl Med. 13:9114
doi: 10.1126/scitranslmed.abj9114
Makunde WH, Msangeni HA, Massaga JJ (2000) Assessment of the efficacy of ivermectin in the treatment of human intestinal helminths and urinary trematode infections in North-East Tanzania. Tanzan Health Res Bull 2000:28–30
Martin RJ, Robertson AP, Choudhary S (2021) Ivermectin: an anthelmintic, an insecticide, and much more. Trends Parasitol 37:48–64
pubmed: 33189582
doi: 10.1016/j.pt.2020.10.005
Mawa PA, Kincaid-Smith J, Tukahebwa EM et al (2021) Schistosomiasis morbidity hotspots: roles of the human host, the parasite and their interface in the development of severe morbidity. Front Immunol 12:635869
pubmed: 33790908
pmcid: 8005546
doi: 10.3389/fimmu.2021.635869
Meshnick SR (1994) The mode of action of antimalarial endoperoxides. Trans Roy Soc Trop Med Hyg 88(Suppl 1):S31–S32
pubmed: 8053021
doi: 10.1016/0035-9203(94)90468-5
Moreira BP, Batista ICA, Tavares NC et al (2022) Docking-based virtual screening enables prioritizing protein kinase inhibitors with in vitro phenotypic activity against Schistosoma mansoni. Front Cell Infect Microbiol 12:913301
pubmed: 35865824
pmcid: 9294739
doi: 10.3389/fcimb.2022.913301
Mu Y, McManus DP, Hou N, Cai P (2021) Schistosome infection and schistosome-derived products as modulators for the prevention and alleviation of immunological disorders. Front Immunol 22(12):619776
doi: 10.3389/fimmu.2021.619776
Njoo FL, Belling GA, Oosting J et al (1993) (1993) Concurrent parasitic infections in onchocerciasis and the occurrence of adverse reactions after ivermectin treatment. Am J Trop Med Hyg 48:652–657
pubmed: 8517484
doi: 10.4269/ajtmh.1993.48.652
Nogueira RA, Lira MGS, Licá ICL et al (2022) Praziquantel: an update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. Mol Biochem Parasitol 252:111531
pubmed: 36375598
doi: 10.1016/j.molbiopara.2022.111531
Oliveira NF (2021) Silva CLM (2021) Unveiling the potential of purinergic signaling in schistosomiasis treatment. Curr Top Med Chem 21:193–204
pubmed: 32972342
doi: 10.2174/1568026620666200924115113
Park SK, Friedrich L, Yahya NA et al (2021) Mechanism of praziquantel action at a parasitic flatworm ion channel. Sci Transl Med. 13(625):eabj5832
pubmed: 34936384
pmcid: 8855674
doi: 10.1126/scitranslmed.abj5832
Piras C, Gugliandolo E, Fabio, et al (2022) Ivermectin (IVM) possible side activities and implications in antimicrobial resistance and animal welfare: the authors’ perspective. Vet Sci 2022(9):24
doi: 10.3390/vetsci9010024
Quadros HC, Silva MCB, Moreira DRM (2022) The role of the iron protoporphyrins heme and hematin in the antimalarial activity of endoperoxide drugs. Pharmaceuticals (Basel, Switzerland) 15(1):60
Reimers N, Homann A, Höschler B et al (2015) Drug-induced exposure of Schistosoma mansoni antigens SmCD59a and SmKK7. PLoS Negl Trop Dis. 9(3):e0003593
pubmed: 25774883
pmcid: 4361651
doi: 10.1371/journal.pntd.0003593
Roquini V, Mengarda AC, Cajas RA et al (2023) The existing drug nifuroxazide as an anti-schistosomal agent: in vitro, in vivo, and in silico studies of macromolecular targets. Microbiol Spectr 11(4):e0139323
Ryan KT, Wheeler NJ, Kamara IK (2023) Phenotypic profiling of macrocyclic lactones on parasitic schistosoma flatworms. Antimicrob Agents Chemother 67:e0123022
pubmed: 36695583
doi: 10.1128/aac.01230-22
Sajid MS, Iqbal Z, Muhammad G, Sandhu MA et al (2007) Effect of ivermectin on the cellular and humoral immune responses of rabbits. Life Sci 80(21):1966–1970
pubmed: 17379254
doi: 10.1016/j.lfs.2007.02.025
Satti MZ, Cahen P, Skov PS, Joseph S et al (2004) Changes in IgE- and antigen-dependent histamine-release in peripheral blood of Schistosoma mansoni- infected Ugandan fishermen after treatment with praziquantel. BMC Immunol 5:6
pubmed: 15102330
pmcid: 419341
doi: 10.1186/1471-2172-5-6
Shafiee A, Teymouri Athar MM et al (2023) A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease? Future Virol. https://doi.org/10.2217/fvl-2023-0006
doi: 10.2217/fvl-2023-0006
pubmed: 36915278
pmcid: 10005062
Shariati F, Pérez-Arellano JL, Carranza C, López-Abán J, Vicente B, Arefi M, Muro A (2011) Evaluation of the role of angiogenic factors in the pathogenesis of schistosomiasis. Exp Parasitol 128:44–49
pubmed: 21296079
doi: 10.1016/j.exppara.2011.01.016
Siddiqui AJ, Khan MF, Hamadou WS et al (2021) Molecular docking and dynamics simulation revealed ivermectin as potential drug against schistosoma-associated bladder cancer targeting protein signaling: computational drug repositioning approach. Medicina (kaunas) 57:1058
pubmed: 34684095
doi: 10.3390/medicina57101058
Spanbenberg T (2021) Alternatives to praziquantel for the prevention and control of schistosomiasis. ACS Infect Dis 7:939–942
doi: 10.1021/acsinfecdis.0c00542
Taman A, El-Beshbishi S, El-Tantawy N et al (2014) Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. J. Coast Life Med 2:817–823 ( https://www.researchgate.net/publication/263466782 )
Vale N, Gouveia MJ, Rinaldi G et al (2017) Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother 61:1–16
doi: 10.1128/AAC.02582-16
Vicente B, López-Abán J, Chaccour J et al (2021) The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice. Sci Rep 11:4476
pubmed: 33627744
pmcid: 7904857
doi: 10.1038/s41598-021-84009-y
Waechtler A, Cezanne B, Maillard D et al (2023) Praziquantel - 50 years of research. ChemMedChem 18:e202300154
pubmed: 37009677
doi: 10.1002/cmdc.202300154
Whitworth JA, Morgan D, Maude GH et al (1991) A field study of the effect of ivermectin on intestinal helminths in man. Trans R Soc Trop Med Hyg 85:232–234
pubmed: 1909471
doi: 10.1016/0035-9203(91)90037-Y
WHO (2023) Schistosomiasis. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
Zech J, Gold D, Salaymeh N, Sasson NC et al (2020) Oral administration of artemisone for the treatment of schistosomiasis: formulation challenges and in vivo efficacy. Pharmaceutics 12:1–17
doi: 10.3390/pharmaceutics12060509